Starting to gather a little momentum, if on the small volume we're used to seeing.
Next look at the cash flows isn't until end of Jan now but nothing stopping them announcing some further contract wins and/or partnerships. Interested to see how much traction Perform8 can generate.
You'd also think further acquisitions would have to be in the plan, given the enterprise solution "cross-sell" model. Given current working capital is utilising the convertible note (and any cash flow) perhaps the idea is to get the sp up a little higher, with any CR being at a less dilutive price, possibly an acquisition for a combination of scrip and cash.
